David J. Moliterno - Concepedia

Author

David J. Moliterno

Also Known As

D J Moliterno, D. J. MOLITERNO, D. J. Moliterno, D.J. Moliterno, DAVID J. MOLITERNO, David J Moliterno, David J. Moliterno, David Moliterno, Franz-Josef Neumann

156

Publications

9.9K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic University of Kentucky Clinical Research Institute University of Alberta Duke Medical Center

About

David J. Moliterno is an author at Cleveland Clinic specializing in medicine, cardiovascular disease, and coronary heart disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	37	3.1K
2	Public Health	11	12	1.3K
3	Health Sciences	3	3	307
4	Cell Biology	1	1	45
5	Diabetes	1	1	429

David J. Moliterno

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction Sorin J. Brener, Lawrence A. Barr, J.E.B. Burchenal, Circulation	1998	723
Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization Eric J. Topol, David J. Moliterno, Howard C. Herrmann, New England Journal of Medicine	2001	678
Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. Koon‐Hou Mak, David J. Moliterno, Christopher B. Granger, Journal of the American College of Cardiology Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseDiabetesPharmacology	1997	429
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention Steven R. Steinhubl, J. David Talley, Gregory A. Braden, Circulation	2001	358
A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes Sunil V. Rao, Kristi O’Grady, Karen S. Pieper, Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseAtherosclerosisCoronary UnitMyocardial Infarction	2006	306
Coronary-Artery Vasoconstriction Induced by Cocaine, Cigarette Smoking, or Both David J. Moliterno, John E. Willard, Richard A. Lange, New England Journal of Medicine	1994	276
Prognostic Importance of Physical Examination for Heart Failure in Non–ST-Elevation Acute Coronary Syndromes Umesh N. Khot, Gang Jia, David J. Moliterno, JAMA	2003	249
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status L. Kristin Newby, E. Magnus Ohman, Robert H. Christenson, Circulation	2001	218
Influence of labetalol on cocaine-induced coronary vasoconstriction in humans James D. Boehrer, David J. Moliterno, John E. Willard, The American Journal of Medicine AddictionMedicinePhysiologyForensic ToxicologyCocaine-induced Coronary Vasoconstriction	1993	196
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction Howard C. Herrmann, David J. Moliterno, E. Magnus Ohman, Journal of the American College of Cardiology Percutaneous Coronary InterventionCardiovascular DiseaseAcute Myocardial InfarctionMedicineCardiology	2000	185

Page 1